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ABSTRACT
Delafloxacin (formerly WQ-3034, ABT492, RX3341) is a novel fluoroquinolone chemically
distinct from currently marketed fluoroquinolones with the absence of a protonatable substituent conferring a weakly acidic
character to the molecule. This property results
in increased intracellular penetration and
enhanced bactericidal activity under acidic
conditions that characterize the infectious
milieu at a number of sites. The enhanced
potency and penetration in low pH environments contrast what has been observed for
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other zwitterionic fluoroquinolones, which
tend to lose antibacterial potency under acidic
conditions, and may be particularly advantageous against methicillin-resistant Staphylococcus aureus, for which the significance of the
intracellular mode of survival is increasingly
being recognized. Delafloxacin is also unique in
its balanced target enzyme inhibition, a property that likely explains the very low frequencies of spontaneous mutations in vitro.
Delafloxacin recently received US Food and
Drug Administration approval for the treatment
of acute bacterial skin and skin structure infections and is currently being evaluated in a phase
3 trial among patients with community-acquired pneumonia. In the current era of a
heightened awareness pertaining to collateral
ecologic damage, safety issues and antimicrobial stewardship principles, it is critical to
describe the unique properties of delafloxacin
and define its potential role in therapy. The
purpose of this article is to review available data
pertaining to delafloxacin’s biochemistry,
pharmacokinetic/pharmacodynamics characteristics, in vitro activity and potential for
resistance selection as well as current progress in
clinical trials to ultimately assist clinicians in
selecting patients who will benefit most from
the distinctive properties of this agent.

Keywords: Acute bacterial skin and skin
structure infection; Antimicrobial stewardship;
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INTRODUCTION
Fluoroquinolones are among the most commonly prescribed antibiotics, accounting for 23
million and 3.8 million oral and injectable prescriptions in the US in 2011, respectively [1, 2].
Attractive features of this class include their
favorable pharmacokinetic (PK) properties,
broad spectrum of activity and clinical efficacy
for a wide range of commonly encountered
infections [3]. However, paralleling the widespread use of fluoroquinolones has been an
alarming increase in the prevalence of fluoroquinolone resistance among clinically relevant
pathogens, underscoring the critical need to
consider antimicrobial stewardship principles
when defining the place in therapy of novel
agents to ensure their utility is not short lived
[4, 5].
Delafloxacin (formerly WQ-3034, ABT492,
RX-3341), a novel dual-targeting anionic fluoroquinolone with useful in vitro activity against
methicillin-resistant
Staphylococcus
aureus
(MRSA), recently received US Food and Drug
Administration (FDA) approval for the treatment of acute bacterial skin and skin structure
infections (ABSSSIs) and is currently being
evaluated in a phase 3 trial for the treatment of
community-acquired pneumonia (CAP) [6].
Fluoroquinolones have not traditionally been
among the first-line options for ABSSSI; however, delafloxacin’s unique structural and
chemical characteristics, which result in
enhanced potency and intracellular penetration
under acidic conditions, suggest it has the
potential to fill a distinctive therapeutic niche
for certain difficult-to-treat infections [7]. Furthermore, its dual targeting mechanism may
serve to limit the emergence of resistance [8].
The purpose of this article is to critically review
available data pertaining to delafloxacin’s biochemistry, pharmacokinetic/pharmacodynamics (PK/PD) characteristics, in vitro activity and
potential for resistance selection as well as current progress in clinical trials to ultimately
delineate future research priorities and assist

clinicians in selecting patients most likely to
benefit from the distinctive properties of this
agent.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Data Sources
Literature searches of MEDLINE (1946 to July
2017) and EMBASE (1974 to July 2017) were
conducted using the search terms ‘‘ABT-492,’’
‘‘WQ-3034,’’ ‘‘RX-3341’’ and ‘‘delafloxacin.’’
Results were limited to articles available in
English. Additional citations were identified
from the references of relevant literature. Current trials focusing on delafloxacin were identified from clinicaltrials.gov. FDA review
documents for the ABSSSI indication were also
examined. Lastly, data were obtained from
conference
proceedings
and
published
abstracts.

CHEMISTRY AND MECHANISM
OF ACTION
The fluoroquinolone class of antibiotics exerts
antimicrobial activity by inhibiting the two key
enzymes, DNA gyrase and topoisomerase IV,
which are essential for replication [9]. Although
all fluoroquinolones in clinical use are active
against both enzymes, they differ in relative
inhibitory potency, with DNA gyrase as the
more sensitive target among gram-negative
bacteria and topoisomerase IV as the preferential target among gram-positive pathogens [9].
Delafloxacin demonstrates more balanced
activity against both enzymes [8]. In theory,
equipotent enzyme inhibition should serve to
limit resistance selection since double mutations are relatively rare genetic events [10].
Delafloxacin demonstrates minimum inhibitory concentrations (MICs) that are consistently three- to five-fold lower than comparator

Infect Dis Ther (2018) 7:197–217

fluoroquinolones against gram-positive organisms. This is thought to be derived in part from
its greater affinity for DNA gyrase compared
with other fluoroquinolones. Because DNA
gyrase acts ahead of the replication fork to
remove positive supercoils, it inhibits DNA
replication more rapidly than the interaction
with topoisomerase IV, which acts behind it
and, as noted, is the preferential target of comparator fluoroquinolones [11]. Delafoxacin’s
increased potency against gram-positive bacteria is also related to its specific shape, size and
polarity [12]. Distinguishing structural characteristics include the presence of a sizable substituted heteroaromatic ring at N1, the absence
of a basic group at C7 and weak polarity defined
by the chlorine atom at C8 (Fig. 1) [12]. The
heteroaromatic ring at N1 increases the solventaccessible surface area, and collaboration
between this large substituent and the weakly
polar group at C8 is thought to influence
potency against quinolone-resistant gram-positive bacteria [12]. It is hypothesized that this C8
substitution could also reduce second-step
resistance development in S. aureus [13, 14]. The
absence of a basic group at C7 gives delafloxacin
an anionic character at neutral pH [7]. This
latter characteristic is unlike the majority of
other fluoroquinolones, which exist as zwitterions at physiologic pH [7]. Under the acidic
conditions that characterize the local environment at many infection sites (urinary tract,

Fig. 1 Chemical structure of delaﬂoxacin
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abscess fluid, decubitis ulcers, epithelial lining
fluid and phagolysosomes of infected cells),
delafloxacin exists predominantly in the neutral
form, which favors uptake by both eukaryotic
cells and bacteria [7]. This is accompanied by
increased activity against both extra- and
intracellular pathogens, in particular S. aureus,
and contrasts what has been observed for other
agents (fluoroquinolones, macrolides, aminoglycosides), which lose antibacterial potency
under acidic conditions [7]. Delafloxacin MICs
against a diverse range of gram-negative and positive organisms decrease four- to seven-fold
as pH in the surrounding media is reduced from
7.2 to 5.5 [15]. The reduction in MICs are most
pronounced among gram-positive bacteria [15].

MICROBIOLOGY
The in vitro activity of delafloxacin and comparator fluoroquinolones against a diverse range
of gram-positive and -negative bacteria are presented in Tables 1 and 2. Minimum inhibitory
concentration (MIC90, range) values are representative of pooled data from studies conducted
with delafloxacin with preference for studies
conducted using isolates collected within the
last 5 years [16, 17]. Standard MIC determination methods are conducted under neutral pH
conditions, and these values may give a conservative estimate of delafloxacin activity under
acidic physiologic conditions.
Among contemporary S. aureus isolates
(MSSA and MRSA), delafloxacin MIC50/90 values
were B 0.004/0.25 mg/l, respectively [18–20].
For a number of bacterial species, including S.
aureus, delafloxacin MICs were bimodal
(0.002–0.003 and 0.06–4 mg/l), presumably
because of existing fluoroquinolone resistance
within the population [20]. Applying the FDA S.
aureus delafloxacin susceptibility MIC breakpoint of 0.25 mg/l to the cumulative MIC values
from a diverse collection of contemporary isolates from US and European medical centers
yields susceptibility rates of 98.7% and 88.0%
for MSSA and MRSA, respectively [6, 19]. The
corresponding levofloxacin susceptibility rates
were 89.8% and 30%, respectively [19].
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Table 1 In vitro activity (MIC, mg/l) of delaﬂoxacin and comparators against aerobic gram-positive bacteria. Adapted from
references [18–20, 23]
Organism

Staphylococcus aureus

Coagulase-negative
Staphylococci

Enterococcus faecalis

Enterococcus faecium

Streptococcus pneumoniae

Streptococcus pyogenes

Phenotype

Delaﬂoxacin

Levoﬂoxacin

Moxiﬂoxacin

MIC90 Range

MIC90 Range

MIC90 Range

All

0.25

B 0.004 to 4 [ 4

B 0.12
to [ 4

MSSA

0.015

B 0.004 to 4

B 0.12
to [ 4

MRSA

0.5

B 0.004 to 4 [4

B 0.12
to [ 4

All

0.5

B 0.004 to 2

1

B 0.12
to [ 4

MSCoNS

0.03

B 0.004 to 1

4

B 0.12
to [ 4

MRCoNS

1

B 0.004 to 2 [ 4

B 0.12
to [ 4

All

1

B 0.004 to 2 [ 4

0.25
to [ 4

VSE

1

B 0.004 to 2 [ 4

0.25
to [ 4

VRE

1

B 0.008 to 2 [ 4

[4

All

[4

0.008 to [ 4 [ 4

0.5 to [ 4

VSE

[4

0.008 to [ 4 [ 4

[4

VRE

[4

[4

[4

[4

All

0.03

B 0.004 to
0.25

1

0.5 to [ 4

PSSP

0.03

B 0.004 to
0.03

1

0.5 to 1

PISP

0.015

0.008 to 0.15 1

0.5 to 1

PRSP

0.03

0.008 to 0.03 1

MDR

0.015

B 0.004 to
0.12

Ceftriaxone nonsusceptible

NR

Levoﬂoxacin resistant

2

0.25

B 0.12 to 4

0.5 to 1

0.25

B 0.12 to
0.25

1

0.5 to [ 4

0.25

B 0.12 to 4

B 0.004 to
0.015

NR

1 to 2

0.5

0.015 to 1

32

2 to 32

4

0.25 to [ 4

0.015

B 0.004 to
0.03

1

0.25
to [ 4

0.25

B 0.12 to
0.5

B 0.12 to
0.25
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Table 1 continued
Organism

Phenotype

Delaﬂoxacin

Levoﬂoxacin

Moxiﬂoxacin

MIC90 Range

MIC90 Range

MIC90 Range

Streptococcus agalactiae

0.03

B 0.004 to
0.5

1

0.25
to [ 4

0.25

B 0.12
to [ 4

Streptococcus dysgalaciae

0.015

B 0.004 to
0.03

1

0.25
to [ 4

0.25

B 0.12 to
0.25

Viridans group
Streptococci

0.06

B 0.004 to 2

2

B 0.12
to [ 4

0.25

B 0.12 to 4

Streptococcus anignosus
group

0.015

0.008 to
0.015

0.5

0.5

Streptococcus mitis group

0.06

0.03 to 0.06

2

1 to 2

Listeria monocytogenes

0.12

0.06 to 0.12

1

1

MIC minimum inhibitory concentration, MRCoNS methicillin-resistant coagulase-negative staphylococcus, MRSA
methicillin-resistant Staphylococcus aureus, MSCoNS methicillin-susceptible coagulase-negative staphylococcus, MSSA
methicillin-susceptible Staphylococcus aureus, NA not applicable, NR not reported, PISP penicillin-intermediate Streptococcus
pneumoniae, PRSP, penicillin-resistant Streptococcus pneumoniae, PSSP penicillin-susceptible Streptococcus pneumoniae, VRE
vancomycin-resistant enterococcus, VSE vancomycin-susceptible enterococcus
McCurdy et al. recently evaluated the activity of delafloxacin against a global collection of
S. aureus isolates (n = 687) from skin and skin
structure infections, of which 34% demonstrated the levofloxacin-resistant phenotype
[18]. Among levofloxacin-susceptible strains,
delafloxacin showed excellent in vitro activity,
and MIC values were not affected by the
methicillin-resistant
phenotype
(MIC90
0.008 mg/l for both MSSA and MRSA). Delafloxacin maintained increased activity against
levofloxacin-resistant MSSA and MRSA isolates;
however, the MIC90 values were increased
32-fold (0.25 mg/l) compared with levofloxacinsusceptible strains [18], which does raise questions pertaining to the risk of selecting resistant
mutants during treatment, particularly in high
inoculum S. aureus infections. Resistance selection studies have indeed demonstrated fewer
passages are required to select mutants with
increased MICs among fluoroquinolone-resistant S. aureus strains compared with sensitive
strains [20]. In the study by McCurdy et al., only

three (0.4%) levofloxacin-resistant MRSA isolates had MIC values above the current delafloxacin S. aureus breakpoint [18].
Delafloxacin also demonstrated potent
activity against S. pneumoniae, and, similar to
earlier respiratory fluoroquinolones, its activity
extends to strains displaying penicillin-resistant
or ceftriaxone non-susceptible phenotypes
[19–22]. In a 2014 surveillance study, all European and 98% of US S. pneumoniae isolates were
inhibited by delafloxacin B 0.03 mg/l [19].
These values are similar to those obtained in a
bacterial respiratory surveillance program conducted 12 years earlier throughout Canada
(CROSS), suggesting that delafloxacin, like
other respiratory fluoroquinolones but in contrast to ciprofloxacin, has maintained its
potency against S. pneumoniae despite the
selective pressure of fluoroquinolone use during
the intervening period [21]. Approximately 1%
of isolates in the US/European surveillance
study
displayed
a
levofloxacin-resistant

Infect Dis Ther (2018) 7:197–217

202

Table 2 In vitro activity (MIC, mg/l) of delaﬂoxacin and comparators against aerobic gram-negative bacteria. Adapted
from references [11, 18–20, 23, 24]
Organism

Delaﬂoxacin

Levoﬂoxacin

Ciproﬂoxacin

MIC90 Range

MIC90 Range

MIC90 Range

All

4

B 0.004
to [ 4

[4

B 0.12
to [ 4

[4

B 0.03
to [ 4

ESBL

[4

0.008
to [ 4

[4

B 0.12
to [ 4

[4

B 0.03
to [ 4

All

[4

0.015
to [ 4

[4

B 0.12
to [ 4

ESBL

[4

0.06 to [ 4 [ 4

B 0.12
to [ 4

0.12

0.03 to 1

B 0.12 B 0.12 to
1

0.06

B 0.03
to [ 4

All

2

0.015
to [ 4

[4

B 0.12
to [ 4

[4

B 0.03
to [ 4

ESBL

[4

2 to [ 4

[4

[4

Enterobacter spp.

1

B0.004
to [ 4

0.5

B 0.12
to [ 4

0.25

B 0.03
to [ 4

Citrobacter spp.

2

0.008
to [ 4

0.5

B 0.12
to [ 4

0.5

B 0.03
to [ 4

Serratia spp.

2

0.03 to [ 4

1

B 0.12
to [ 4

1

B 0.03
to [ 4

Providencia spp.

0.12

0.008 to 0.5 0.25

Morganella morganii

4

0.12 to 4

[4

B 0.12
to [ 4

4

0.008
to [ 4

[4

B 0.12
to [ 4

[4

B 0.03
to [ 4

Salmonella spp.

0.06

0.008 to 0.5 0.06

0.015 to 1

0.015

0.002 to
0.25

Shigella spp.

NR

0.002 to
0.008

NR

0.004 to
0.015

Pseudomonas aeruginosa

[4

0.015
to [ 4

[4

B 0.12
to [ 4

[4

B 0.03
to [ 4

Acinetobacter baumannii–A.
calcoaceticus

[4

0.015
to [ 4

[4

B 0.12
to [ 4

[4

0.06
to [ 4

Escherichia coli

Klebsiella pneumoniae

Phenotype

Klebseilla oxytoca
Proteus mirabilis

Proteus spp.

Indole-positive

0.12 to
0.25
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Table 2 continued
Organism

Delaﬂoxacin

Levoﬂoxacin

Ciproﬂoxacin

MIC90 Range

MIC90 Range

MIC90 Range

Ciproﬂoxacin
susceptible

NR

0.25

NR

1

NR

Ciproﬂoxacin
resistant

16

0.25 to 16

[ 128

2 to [ 128 [ 128

2 to [ 128

Haemophilus inﬂuenza

0.004

B 0.001 to
0.25

0.03

0.008
to [ 2

0.015

0.004
to [ 2

Moraxella catarrhalis

0.008

0.004 to
0.015

0.06

0.03 to
0.12

0.06

0.015 to
0.06

Neisseria gonorrhea

0.06

0.125

16

0.004
to [ 16

Burkholder cepacia

Phenotype

1

ESBL extended-spectrum beta-lactamase, MIC minimum inhibitory concentration, NA not applicable, NR not reported

phenotype (MIC [ 4 mg/l), and all were inhibited by delafloxacin B 0.25 mg/l [19].
Delafloxacin is also very active against gramnegative respiratory pathogens. Haemophilus
influenzae and Moraxella catarrhalis MIC90 values
were B 0.004 and 0.008 mg/l, respectively [22].
Due to the paucity of clinical data pertaining to
outcomes with the use of delafloxacin for the
treatment of respiratory tract infections at this
time, the clinical breakpoints for these three
pathogens have not yet been established.
The MIC90 value of contemporary Enterococcus faecalis isolates from both clinical and
surveillance studies was 1 mg/l with a range
of B 0.004 to 2 mg/l (Table 1) [18–20, 23].
Among levofloxacin-resistant E. faecalis isolates,
delafloxacin’s MIC50/90 values were 0.25 and
8 mg/l, respectively [23]. In the absence of
clinical efficacy or PK/PD studies conducted
with E. faecalis, the interpretive breakpoint
of B 0.12 mg/l was established by the FDA,
which is many fold lower than the observed
MIC90 values [20]. As shown in Table 1, delafloxacin is not expected to have useful activity
against E. faecium (MIC90 [ 4 mg/l) [19, 20].
The in vitro activity of delafloxacin and fluoroquinolone comparators against a broad

range of contemporary aerobic gram-negative
bacteria is presented in Table 2. As shown,
delafloxacin MIC90 values for E. coli and Klebsiella pneumoniae exceed the clinical breakpoint
of B 0.25 mg/l by 16-fold and [ 16-fold,
respectively [19, 20]. The levofloxacin-resistant
phenotype was observed in approximately 30%
and 20% of isolates, respectively, in these
studies [19, 20]. In the surveillance study by
Pfaller et al., delafloxacin susceptibility rates
among US E. coli and K. pneumoniae isolates
were 65% and 78%, respectively [19]. Among
isolates with the ESBL phenotype, susceptibility
rates were just 17.3% and 5.7%, respectively
[19]. Against Enterobacter spp., delafloxacin
appears less active than levofloxacin. Delafloxacin demonstrated more potent activity
against K. oxytoca with MIC90 values of 0.12 mg/
l [19, 20]. As shown in Table 2, delafloxacin
activity against Pseudomonas aeruginosa (MIC50/
90 0.25/4 mg/l; 65% susceptible) is similar to
comparator
anti-pseudomonal
fluoroquinolones [19, 20].
Clinical experience with the indicated gramnegative pathogens has been very limited with
most non-surveillance isolates cultured from
poly-microbial infections in ABSSSI studies
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[18, 20]. If the use of delafloxacin is contemplated for infections in which gram-negative
bacilli are common pathogens, additional clinical data are needed to better determine how
MIC values measured by standard methods
should inform treatment decisions.
Delafloxacin has shown excellent in vitro
activity against Neisseria gonorrheae including
ciprofloxacin-resistant and multidrug-resistant
(MDR) strains (Table 2) [24]. Against a panel of
N. gonorrheae clinical isolates collected from
medical centers across the US during 2012 to
2015, including 67.5% with the ciprofloxacinresistant phenotype, the delafloxacin MIC90
value was 0.125 mg/l [24]. Lessons from the past
however have shown that findings from in vitro
studies may not be entirely predictive of clinical
outcomes for N. gonorrheae infection [25].
Unfortunately, a phase 3 trial comparing a single oral dose of delafloxacin (900 mg) to ceftriaxone for the treatment of uncomplicated
gonorrhea (NCT02015637) was terminated
early in 2015 for reasons of insufficient efficacy
following an independent interim review [26].
The in vitro activity of delafloxacin against
Mycobacterium tuberculosis and M. avium was
evaluated in a single study [27]. Delafloxacin
was more efficacious than levofloxacin at
inhibiting intracellular macrophage growth of
M. tuberculosis. It is hypothesized that this
observation may be related to improved delivery of delafloxacin to the phagosomes of MM6M/s that engulf bacteria. Additionally, the
potentiation of delafloxacin’s antimicrobial
activity under the acidic conditions that are
characteristic of the macrophage phagosomes
that engulf mycobacterial pathogens may be
particularly advantageous [27]. Further support
for delafloxacin’s ability to accumulate and
exert antibacterial activity within mammalian
cells comes from demonstrations of its activity
against Chlamydia spp., an obligate intracellular
pathogen, with MICs ranging from 0.03 to
0.06 mg/l [11].
Few studies have evaluated the activity of
delafloxacin against clinically relevant anaerobic organisms [11, 28]. Potent activity was
demonstrated against Bacteroides fragilis in particular in one study, with an MIC90 value of
0.125 mg/l [28]. Caution is advised when
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interpreting the findings because isolates were
collected nearly 15 years ago, and in the intervening period fluoroquinolone resistance
among key anaerobic bacteria has increased
significantly [16, 29]. More recent US surveillance data testing isolates collected during 2010
to 2012 have shown much lower susceptibility
rates for moxifloxacin against key anaerobic
species [16, 29]. Although the potential for
cross-resistance among anaerobic species for
delafloxacin and other fluoroquinolones has
not been explored, high levels of cross-resistance have been documented between earlier
fluoroquinolones.
More contemporary data pertaining to delafloxacin’s activity against Clostridium difficile
has been presented. Vernon et al. investigated
the in vitro activity of delafloxacin and comparator agents against prevalent C. difficile
ribotypes (RTs) [30]. Delafloxacin’s geometric
mean (GM) MIC overall was 0.37 mg/l. Large
differences in activity were observed for isolates
belonging to the hypervirulent RT027 compared with non-RT027 (GM MIC 4.0, 0.13 mg/l,
respectively), suggesting delafloxacin shares in
the universal fluoroquinolone class resistance in
this troublesome strain [30].

PHARMACOKINETICS
The PK properties of delafloxacin have been
evaluated in phase 1 and 3 studies utilizing
single and multiple ascending doses ranging
from 300 to 1200 mg (IV) and 50 to 1600 mg
(oral) [31–33]. As shown in Table 3, at steady
state, delafloxacin, administered as 300 mg IV
every 12 h, achieves a maximum serum concentration (Cmax) of 9.29 mg/l and total exposure (AUC from 0 to 12 h, AUCs) of 23.4 mg h/l.
The bioavailability of the tablet formulation is
59%, which is lower than that of other fluoroquinolones such as levofloxacin and moxifloxacin (99% and 92%, respectively; Table 3);
however, the AUCs of delafloxacin 450 mg
administered orally (20.6 mg h/l) is comparable
to that achieved with a labeled IV dose of
300 mg [6, 32–34]. Both the IV and oral formulations demonstrate approximate dose proportional increases in exposure following single
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Table 3 Pharmacokinetic parameters of delaﬂoxacin and comparator ﬂuoroquinolones. Adapted from references
[6, 33–35]
Parameter

Delaﬂoxacin IV
(300 mg, every
12 h)

Vd (l)

35–48

Cmax (mg/l)

9.29

fCmax (mg/l)

Delaﬂoxacin PO
(450 mg, every
12 h)

Levoﬂoxacin PO
(750 mg, every
24 h)

Ciproﬂoxacin PO Moxiﬂoxacin PO
(500 mg, every
(400 mg, every
12 h)
12 h)

100

84–189a

119–189a

7.45

8.6

3.0

4.5

1.49

1.19

5.3–6.5

1.8–2.4

2.25–3.15

AUC0–s
(mg h/l)

30.8

23.4

90.7

13.7

48

fAUC0–s
(mg h/l)

4.93

3.74

56.2–68.9

8.2–11.0

24–33.6

AUC24 (mg h/
l)

61.6

46.8

90.7

27.4

48

fAUC24 (mg h/ 9.86
l)

7.48

56.2–68.9

16.4–22.0

24–33.6

24–38%

20–40%

30–50%

4.2–8.5

8.8

4–6

10–14

50.2%:47.7%

87%:4%

57%:20–35%

20%:25%

58.8%

99%

70%

92%

Limited?

Oxidation?

Sulfation,
glucuronidation

Protein binding 84%
T1/2 (h)
Elimination
(urine:feces)

3.7b
64.5%:28.4%

b

Oral
N/A
bioavailability
Metabolism

Glucuronidationc

Vd volume of distribution, Cmax peak serum concentration, fCmax free peak concentration, AUC0–s area under the curve
over the dosing interval, fAUC0-s free area under the curve over the dosing interval, AUC24 area under the curve over 24 h,
fAUC24 free area under the curve over 24 h, T1/2 half- life
a
Based on a 70-kg adult
b
After a single dose
c
No signiﬁcant circulating metabolites

doses ranging up to 1200 and 1600 mg, respectively [32, 33]. The Cmax is reduced 20%, and
the time to Cmax (Tmax) is doubled when delafloxacin tablets are administered with food
compared with the fasting state. However, total
delafloxacin exposure (AUCs) is similar when
administered with or without food; thus, PK
changes secondary to food intake around the
time of dosing are not expected to affect clinical
outcomes [32, 33].

Delafloxacin volumes of distribution have
ranged from 35 to 48 l across studies. Protein
binding (primarily to albumin) is approximately
84% (Table 3) [6, 33–35]. Delafloxacin shares
the fluoroquinolone class characteristic of high
pulmonary distribution with a 13:1 mean penetration ratio into the epithelial lining fluid vs.
free plasma concentration [36]. Data pertaining
to the distribution characteristics of delafloxacin in other tissues have not been reported
at this time.
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Delafloxacin is primarily metabolized
through glucuronidation, with oxidative metabolism accounting for approximately 1% of the
administered dose, suggesting a low potential
for drug interactions. The predominant route of
elimination is renal (50–65%) with the remainder of elimination occurring in the feces as
unchanged drug. Delafloxacin’s half-life was
3.7 h following a single IV 300 mg dose and
ranged from 4.2 to 8.5 h following multiple oral
doses [6, 33, 37].
PK parameters of delafloxacin have been
examined in patients with varying degrees of
renal impairment [33]. Delafloxacin exposure
has consistently been shown to increase with
decreasing renal function; however, clinically
important differences are not apparent until the
estimated glomerular filtration rate (eGFR) as
calculated using the Modification of Diet in
Renal Disease equation (MDRD) is under 30 ml/
min/1.73 m2. The AUCs increased 1.8-fold in
patients with severe renal impairment (eGFR
15–29 ml/min/1.73 m2) following a single
300 mg IV dose. The corresponding fold changes in total exposure among patients with endstage renal disease (ESRD) when delafloxacin
was administered before and after hemodialysis
(HD) were 2.1 and 2.6, respectively. Decreased
plasma protein binding has also been observed
in subjects with severe renal impairment and
ESRD (80% and 75%, respectively). Based on
population PK simulations, an adjusted dose of
200 mg IV every 12 h is recommended for
patients with severe renal impairment [6, 33].
The lower dose also reduces the risk for adverse
renal effects secondary to sulfobutylether-betacyclodextrin (SBECD, an excipient in the IV
formulation) accumulation [33].
Decreasing renal function does not appear to
greatly impact the exposure of delafloxacin
tablets; drug exposure was 1.5-fold higher in
subjects with severe renal impairment following
oral administration (450 mg) compared with
subjects with normal renal function. A dosing
regimen of 450 mg IV every 12 h produced
exposures in patients with normal renal function similar to those achieved in patients with
severe renal impairment that were administered
the 450-mg oral dose, and tolerability was
acceptable at these exposures [33]. Thus, dosage
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adjustment of the oral formulation for patients
with severe renal impairment is not recommended. Currently, there are no explicit labeled
recommendations for dosing in patients maintained on HD. Twenty percent of the drug is
removed during a 4-h HD session [6].
The PK profile of delafloxacin has been
evaluated in subjects with varying degrees of
hepatic impairment. Total AUC values were
similar in patients with normal, mild and
moderate hepatic function. Higher PK variability was observed in patients with severe hepatic
impairment, and total exposure was increased
approximately 40% compared with controls.
These differences are unlikely to be clinically
important, and dosage adjustment in this population is not recommended [33].

PHARMACODYNAMICS
Similar to other fluoroquinolones, delafloxacin
exhibits concentration-dependent antimicrobial activity, and the unbound drug AUC over
24 h divided by the MIC of the pathogen
(fAUC24/MIC) is the PK/PD parameter most
closely associated with delafloxacin activity
[33, 38]. The PD target value for delafloxacin
against S. aureus was determined in a series of
experiments using the murine neutropenic
thigh infection model [33]. Animals were inoculated with 106 CFU of MSSA or MRSA possessing delafloxacin MICs ranging from 0.004 to
0.006 mg/l and 0.016 to 0.8 mg/l, respectively.
Delafloxacin (1.25 to 320 mg/kg) was administered as a single dose, and the bacterial burden
was determined 24 h after dosing. The median
fAUC24/MIC ratios associated with net bacterial
stasis and a 1-log10 CFU reduction were 9.3 and
14.3, respectively. Utilizing a murine lung
infection model for collection of MSSA and
MRSA isolates with MICs ranging from 0.004 to
0.008 mg/l, Andes et al. documented substantially lower median target ratios (stasis 1.74 and
1-log10 CFU reduction 7.92) [39]. Similarly, the
median fAUC24/MIC ratio of delafloxacin to
achieve either stasis or 1-log10 CFU reduction in
a neutropenic murine lung model by Thabit
et
al.
utilizing
MSSA
isolates
(MIC
0.002–0.52 mg/l) was 0.4 [36]. However, the
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corresponding target ratios for MRSA isolates
with baseline MICs of 0.25–1 mg/l were markedly higher in this study (stasis 8.1 and 1-log10
CFU reduction 24.7) and more closely aligned
to those generally quoted for fluoroquinolones
against gram-positive cocci (fAUC24/MIC C 25)
[36, 38]. Thus, it appears that PK/PD targets for
delafloxacin may differ between stains, phenotypes and site of infection.
Similar experiments were also conducted to
determine the threshold fAUC24/MIC ratios
associated with efficacy against E. coli and P.
aeruginosa. Findings indicated mean fAUC24/
MIC targets for bacterial stasis and a 1-log10 CFU
reduction for E. coli were 14.5 and 26.2,
respectively, while the corresponding fAUC24/
MIC targets for P. aeruginosa were 3.8 and 5.0,
respectively.
Staphylococcus aureus is frequently associated
with biofilm-related infections, which are particularly difficult to treat because antibiotics
tend to be much less active against bacteria
embedded in biofilm compared with those in
the planktonic state [40]. The increased potency
of delafloxacin under acidic conditions may be
particularly advantageous in this setting [7].
Utilizing an in vitro PD model of mature S.
aureus biofilms, Bauer et al. reported that delafloxacin reduced both MSSA and MRSA biofilm
viability by at least 50% at clinically achievable
concentrations [41]. Delafloxacin, oxacillin
(MSSA) and daptomycin were the most efficacious among a panel of nine anti-staphylococcal agents. The interpretation of these findings
is somewhat hampered by the use of reference S.
aureus strains displaying MICs that are 4(MSSA) and 125-fold (MRSA) lower than MIC90
values documented in contemporary surveillance studies [41].
In a second biofilm study using MSSA and
MRSA with a broader range of delafloxacin MIC
values (0.004–0.125 mg/l), delafloxacin displayed potent activity at clinically achievable
concentrations against five of the seven isolates
tested [42]. Investigators did not account for
delafloxacin protein binding (84%) when considering achievable Cmax values in vivo
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however. The penetration of delafloxacin
within the biofilm was observed to range from
0.62% to 51.8% and was generally greater in
biofilms with lower pH values [42].
Renal abscesses involving S. aureus are challenging to treat with currently available agents
because of the presence of a large proportion of
bacteria in the stationary phase of growth, and
the local environment is usually characterized
by low pH values [7]. Ding et al. investigated the
comparative activity of delafloxacin and moxifloxacin against renal abscesses formed by a
community-associated MRSA strain (MW2) in a
murine model of systemic infection [43]. Both
delafloxacin and moxifloxacin reduced the
bacterial load in renal abscesses compared with
controls. The reduction of the bacterial burden
by delafloxacin was significantly greater than
that by moxifloxacin [43].
Delafloxacin
has
also
demonstrated
increased activity against gram-negative pathogens under acidic experimental conditions. So
et al. examined the effect of urine matrix and its
varying pH on the activity of delafloxacin and
ciprofloxacin against 16 MDR urogenic E. coli
and K. pneumoniae [44]. All isolates were resistant to both ciprofloxacin (MIC 32 to [ 64 mg/
l) and delafloxacin (MIC 2–16 mg/l) at baseline
when measured in standard media. Similar to
results obtained for delafloxacin against grampositive pathogens tested under acidic experimental conditions [7], delafloxacin MICs
decreased by 1–3 doubling dilutions in 53% and
68% of observations for E. coli and K. pneumoniae, respectively, when MIC testing was performed in acidic urine. By contrast, MICs for
ciprofloxacin remained relatively unchanged
across the range of pH values tested [7]. Even
with the maximal MIC reductions when using
urine as the test media, most isolates would
continue to demonstrate MICs far above the
current delafloxacin Enterobacteriaceae interpretive breakpoint of B 0.25 mg/l; thus, the
clinical implications of this study as relates to
the potential utility of delafloxacin in the
treatment of MDR Enterobacteriaceae are not
entirely clear [6, 44].
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RESISTANCE
Resistance to fluoroquinolones most commonly
involves step-wise chromosomal mutations in
the quinolone resistance-determining regions
(QRDR) of DNA gyrase (gyrA) and/or topoisomerase IV (parC/grlA). Overexpression of efflux
pumps and decreased uptake secondary to
reduced expression of outer membrane porins
may also contribute to chromosomal resistance
[9, 45]. Finally, plasmid-mediated fluoroquinolone resistance is an emerging concern
[45].
Delafloxacin maintains clinically useful
activity against a range of bacteria displaying
the quinolone-resistant phenotype secondary to
single and double mutations in the QRDR as
well as efflux pump expression. The ability of
delafloxacin to select for spontaneous mutations within the QRDR or efflux pump gene loci
in vitro has been investigated in a number of
studies using both naı̈ve strains and those with
pre-existing mutations. Remy et al. conducted a
series of spontaneous resistance selection
experiments using four strains of S. aureus, three
of which carried pre-existing mutations in the
QRDR [8]. The observed resistance frequencies
were low (6.0 9 10-9 to \ 9.5 9 10-9) for delafloxacin at two times the baseline MIC and
similar to those demonstrated for moxifloxacin
[8]. The resistance frequencies of both drugs
were substantially less than that of levofloxacin.
Notably, no delafloxacin-resistant strains could
be isolated from the strain that had no pre-existing QRDR mutations [6]. The minimum protective concentration in the present study
ranged from one to four times the initial MIC
for all quinolones tested. Delafloxacin-resistant
mutants maintained their reduced susceptibility
following passage in drug-free media for 7 days,
suggesting a stable phenotype [8, 46].
Whole-genome sequencing characterized the
nature of the mutations of the resultant variants. Delafloxacin-selected variants with MIC
shifts B 4-fold of the parent strain showed no
genetic changes in the QRDR or the norA loci,
which encodes for the predominant fluoroquinolone efflux pump in S. aureus. Mutant
strains with delafloxacin MICs C 8-fold those of
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the parent strain were characterized by both
previously described and novel mutations in
gryA and gyrB. Two variant isolates, both with
MICs of 4 mg/l and selected from a parent strain
with pre-existing gyrA and grlA mutations,
showed no changes in the QRDR or the norA
sequence and its surrounding regulatory
regions, suggesting delafloxacin resistance may
arise through previously uncharacterized
mechanisms [8].

CLINICAL EFFICACY
The clinical efficacy of delafloxacin has been
evaluated in phase 2 and phase 3 studies among
patients with ABSSSI as well as phase 2 studies
among patients with acute exacerbation of
chronic obstructive pulmonary disease and CAP
[47–52].
The first clinical study to evaluate delafloxacin in the treatment of ABSSSIs was a phase
2 randomized, double-blind, multicenter, doseranging comparative study [48]. Adults with
wound infection, abscess or cellulitis were
enrolled from 14 centers in the US; patients
(n = 150) were randomized to delafloxacin 300
or 450 mg, each administered IV, every 12 h or
tigecycline 100 mg IV once, followed by 50 mg
IV, every 12 h for 5–14 days [48]. S. aureus
comprised nearly 90% of gram-positive pathogens, and methicillin-resistance was detected in
71%. Clinical cure rates and microbiologic
eradication rates exceeded 90% in all treatment
groups with no between-group differences.
Kingsley et al. performed the second phase 2
ABSSSI multicenter, randomized, double-blind
trial evaluating delafloxacin (300 mg) versus
linezolid (600 mg) and vancomycin (15 mg/kg,
actual body weight; maximum 1250 mg; target
trough 15–20 mg/l), each administered IV twice
daily for 5–14 days [47]. The addition of blinded
aztreonam was permitted for patients with
gram-negative infections randomized to linezolid or vancomycin. In total, 256 patients
comprised the intention-to-treat population
(ITT). S. aureus was the most frequently isolated
organism with 67% of strains displaying the
methicillin-resistant phenotype [47]. Cure rates
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at the follow-up time point (day 14) were 70.4%
in the delafloxacin group compared with 64.9%
in the linezolid group (P = 0.496 vs. delafloxacin) and 54.1% in the vancomycin group
(P = 0.031 vs. delafloxacin). The higher cure
rate in the delafloxacin vs. vancomycin group
appeared to be driven by patients with a body
mass index (BMI) C 30 kg/m2 (78.8% vs. 48.8%;
P = 0.009). Among the microbiologically
evaluable population (n = 125), presumed or
documented eradication rates were similar
between groups and ranged from 80.8% to
88.2% [47].
There are several limitations to these studies
that deserve comment. Importantly, as phase 2
trials, they were not designed with a formal prespecified hypothesis or powered for any inferential statistical testing. Both trials included a
relatively small number of patients and, as a
consequence, the range of bacterial pathogens
recovered was limited. Furthermore, patients
most at risk for infection with a broader range of
bacterial species (i.e., those who are immunocompromised or have severe underlying
comorbidity) and who therefore may stand to
benefit from delafloxacin’s expanded spectrum
of activity, were excluded from the studies. The
MRSA MICs for delafloxacin were considerably
lower than has been observed in recent
surveillance studies [20, 47, 48]. All patients
were enrolled from US centers, which raises the
question of whether the data are applicable
across
geographic
populations.
Finally,
although most patients were treated in the
outpatient setting, the efficacy of the oral formulation of delafloxacin was not evaluated.
To address these limitations as well as fulfill
regulatory drug approval requirements, two
phase 3 studies evaluating delafloxacin for the
treatment of adult patients with ABSSSIs were
initiated in 2013 (NCT01811732/RX-3341-302
and NCT1984684/RX-3341-303, hereafter referred to as study 302 and 303, respectively) [51, 52].
Both were multicenter, randomized, doubleblind, non-inferiority studies comparing delafloxacin (300 mg) with vancomycin (15 mg/kg
actual body weight) plus aztreonam (2 g), each
administered IV, every 12 h for 5–14 days
[51, 52]. In study 303, a switch to oral delafloxacin (450 mg) was mandated following six IV
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doses except for patients with an eGFR 15–29 ml/
min who were to receive delafloxacin 200 mg IV
every 12 h for all doses [51, 52]. If gram-negative
pathogens were not isolated on the baseline
culture, aztreonam was discontinued. No similar
de-escalation to targeted therapy occurred for
patients in the delafloxacin arms. Patients with
infections involving prosthetic material or associated with human/animal bites, osteomyelitis,
decubitus ulcer, diabetic foot ulcer, septic
arthritis, necrotizing fasciitis or burns covering C 10% of the body surface area were not eligible for enrollment. Other key exclusion criteria
included severe underlying comorbidity (liver
disease, end-stage renal disease, cardiac disease,
malignancy), history of seizure disorder and
pregnancy or lactation. The primary endpoint in
the two studies was C 20% reduction in lesion
size at 48–72 h in the ITT population. In study
303, enrollment was expanded above the calculated sample size to enrich for a pre-specified
subgroup analysis by BMI [51, 52].
In total, 660 and 850 patients were randomized in study 302 and 303, respectively. In
both studies, the majority of patients were
enrolled from US centers. The mean age of
participants was approximately 46 and 50 years
in study 302 and 303, respectively. Few patients
aged 65 years and older were enrolled (7% and
20%, respectively). Approximately 80–90% of
patients were Caucasian; African American
patients were under-represented (7% and 20%).
Obese patients (BMI C 30 kg/m2) comprised
32% and 40% of the study populations. Eight to
13% of patients carried a diagnosis of diabetes,
and approximately 1% had severely decreased
renal function (eGFR \ 30 ml/min). Bacteremia
was rare in both studies (2.3%, 2.2%) [51, 52].
The most prevalent pathogen isolated from
the infection site was S. aureus, which was
identified in 66% and 58% of the microbiologic
ITT (MITT) patients in study 302 and 303,
respectively. MRSA accounted for 52% and 36%
of the S. aureus isolates, respectively [51, 52].
Delafloxacin was non-inferior to vancomycin plus aztreonam for the primary endpoint in both trials. Outcomes at the end of the
therapy time point (14 ± 1 day) were similar,
suggesting a sustained response to treatment in
all groups. Importantly, outcomes at the later
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time points in study 303 are supportive of oral
delafloxacin, which would have been initiated
following assessment of the primary outcome.
Among the MITT population, per pathogen
response rates were generally similar between
treatment groups across all pathogens. Overall,
66% of MRSA isolates were levofloxacin nonsusceptible [51]. Among these isolates, the
delafloxacin MIC90 value was 0.25 mg/l, and the
eradication or presumed eradication rate was
98.6%. One MRSA isolate displayed an MIC of
4 mg/l, and double mutations in both gyrA and
parC were subsequently confirmed. The microbiologic response for the patient with this isolate was presumed eradicated based on clinical
response. Approximately 15% of isolates recovered were gram-negative. The predominant
gram-negative pathogens were K. pneumoniae
and E. coli. Levofloxacin non-susceptibility was
low among K. pneumoniae (2.2%), and most
were susceptible to delafloxacin (MIC50/90 0.12/
0.25 mg/l). Levofloxacin non-susceptibility was
slightly higher among E. coli, and the delafloxacin MIC90 was 4 mg/l [51].
Subgroup analysis by age, sex, race and geographic region were consistent with the overall
results; however, analysis is limited by the small
number of patients in some subgroups, particularly those from regions outside of the US and
African American patients [51, 52].
In study 302, an exploratory post hoc analysis by BMI category suggested a significant
improvement in cure rates at the long-term
follow-up time point among obese patients
assigned to delafloxacin compared with vancomycin (71.7% vs. 57.5%; treatment difference
14.2%, 95% CI 1.3% to 26.9%) [51, 52]. This
finding however was not subsequently confirmed in study 303, which, as noted previously,
was enriched with obese patients to allow for
formal statistical testing of this hypothesis.
Among obese patients the cure rates at the late
follow-up time point were similar (68.3% vs.
71.0%; treatment difference -2.7%, 95%
CI - 11.5% to 6.0%). Information pertaining to
vancomycin trough target attainment has not
been reported for the overall study populations
or by BMI category [51, 52].
Although these studies addressed several
limitations of the phase 2 studies including a
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larger number of patients and conducting formal hypothesis testing, they did not expand
knowledge of delafloxacin’s performance
among patients at risk for a broader range of
pathogens. Key populations including the
elderly, those with organ dysfunction, and
those with significant underlying comorbidity
were either excluded or under-represented.
Furthermore, although too few gram-negative
isolates were collected to allow for meaningful
analysis, the high delafloxacin MIC values displayed among those that were obtained suggest
delafloxacin may not be an ideal option when
these pathogens are suspected, although, as
noted previously, MIC values determined by
standard methods may underestimate in vivo
activity.
The efficacy of delafloxacin has also been
explored among patients with respiratory tract
infections [49, 50]. Longcor et al. conducted a
phase 2, double-bind, randomized, dose-ranging study comparing three dose ranges of oral
delafloxacin (100, 200, 400 mg daily 9 5 days)
to levofloxacin (500 mg daily 9 7 days) in adult
outpatients diagnosed with ABECB [49]. In
total, 280 patients were randomized with a
mean age of 61 years. Clinical cure rates were
similar in the four groups (69–79%), and no
dose-response trend was identified. Regarding
bacteriologic cure rates, however, outcomes
were improved among patients assigned to
delafloxacin 400 mg compared with the lower
doses. In the phase 2 study evaluating the
clinical and bacteriologic outcomes with
ascending delafloxacin doses (100, 200 or
400 mg once daily for 7 day) among adult outpatients with CAP (n = 309), clinical and bacteriologic cure rates were similar in the 200 and
400 mg groups and slightly lower for the
100 mg group [50].
While the results of these studies are
encouraging and appear to support a role for
delafloxacin in the treatment of bacterial respiratory tract infections, further data from an
ongoing phase 3 study comparing delafloxacin
to moxifloxacin or linezolid for the treatment
CAP (NCT02679573) are required before
definitive conclusions pertaining to its efficacy
for respiratory infections can be made.
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ADVERSE EFFECTS
For many years, fluoroquinolones were considered a safe and generally well-tolerated class of
antimicrobials [53]. In recent decades, however,
safety concerns have led to restrictions on the
use of fluoroquinolones and, in some instances,
withdrawal of agents from the market [53, 54].
Recently, the FDA advisory committees on
antimicrobial drugs and drug safety concluded
that a risk vs. benefit analysis did not support
the use of these agents in a number of uncomplicated infections, and labeling of all marketed
fluoroquinolones has been updated to include
stronger warnings pertaining to the risks serious
adverse effects (AEs) such as tendon rupture,
peripheral neuropathy and central nervous system (CNS) disturbances [55]. Distinct differences among fluoroquinolones with regard to
their safety profile can be predicted in part by
structural differences with structure-AE relationships based on constituents at specific sites
on the quinolone nucleus [54]. Delafloxacin has
a number of unique structural characteristics,
however, which present challenges when
attempting to predict the potential for serious
AEs by this approach.
As with all fluoroquinolones, the most
commonly reported AEs in phase 3 delafloxacin
trials were gastrointestinal (GI) related (diarrhea
8%, nausea 8%) or mild CNS events [56]. Data
from phase 1 and 2 studies indicate an association between GI AEs and higher doses [56].
There does not appear to be a clear fluoroquinolone structure-GI AE relationship, but
rather GI AEs are thought to be due to direct GI
irritation and/or indirect CNS effects [53].
Tendinopathies are rare AEs associated with
fluoroquinolones [57]. Although there has not
been a widely accepted structural moiety associated with tendinopathy, animal models suggest structural differences at position 7 may play
a role with a methypiperadinyl group causing
the highest number of tendon lesions [57].
Delafloxacin is the only marketed fluoroquinolone with a weakly acidic substituent at
this position [58]. Three patients in pooled
phase 3 delafloxacin trials reported tendonitis
[56]. One event was graded as moderate in
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severity, and all other events were considered to
be mild. Predisposing factors such as concomitant steroid use and renal disease were not present in any of the affected patients [56].
AEs involving the CNS have generally been
the second most commonly encountered form
of fluoroquinolone toxicity and include a broad
variety of effects ranging from headaches and
dizziness to acute psychosis to seizures [54].
These effects are thought to occur secondary to
fluoroquinolone blockade of GABA receptors
[53, 54]. In vitro experiments suggest that the
delafloxacin concentrations required to inhibit
GABA are many fold above those achieved
clinically [56]. In line with these experimental
observations, headache occurred in just 3% of
delafloxacin-treated patients in pooled phase 3
trials, and other CNS AEs were relatively rare
[56]. No patients in the delafloxacin arms of
phase 3 studies experienced seizures or convulsions [56]. One patient who received a higher
than labeled dose of delafloxacin (450 mg IV)
during a phase 2 study experienced a seizure
[56].
Structural differences at positions 1, 5 and 8
of the quinolone nucleus influence the phototoxic potential [54]. Fluoroquinolones with a
halogen at position 8 of the nucleus along with
a bulky side chain are well known for their
associated phototoxicity [53]. A methyl group at
position 5 may also contribute [53]. Delafloxacin contains a chlorine at position 8 but
lacks a bulky side chain and contains no R5
substituent [58]. A phase 1 study investigating
the photosensitizing potential of delafloxacin
demonstrated findings similar to placebo with
no evidence of phototoxicity in either the low
(200 mg) or high (400 mg) dose arms of delafloxacin-treated subjects [56]. By comparison,
more subjects assigned to the positive control
group (lomefloxacin) exhibited both mild and
severe phototoxicity at various wavelengths.
Assessment of the hepatotoxic potential of
delafloxacin is limited by the relatively small
number of patients who have been exposed at
this time. Although case reports of severe liver
injury emerged soon after trovafloxacin was
introduced into the clinic, it was not until
approximately 2.5 million courses of therapy
had been administered that the causal
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relationship was deemed strong enough to
warrant its removal from the market [59]. The
frequency of clinically significant elevations
([ 5 times the upper limit of normal) of aspartate aminotransferase, alanine aminotransferase
and alkaline phosphatase was 0.3% or less
across delafloxacin groups in phase 3 trials, and
no clinically significant elevations in bilirubin
occurred [56]. These parameters may be poorly
predictive of the potential for drug-induced
hepatotoxicity however.
The main area of interest relating to the
cardiac toxicity of fluoroquinolones is prolongation of the QTc interval [59]. The mechanism
by which this occurs is likely multifactorial, and
an obvious structural moiety that increases the
risk for QTc prolongation has not yet been
identified [54]. Studies of various fluoroquinolones have shown a dose-dependent
inhibition of the rapid-acting portion of the
delayed rectifier potassium current, which is
controlled by the human ether-a-go-go gene
(HERG) [60]. Preclinical studies with delafloxacin have found that it did not block HERG
currents. In a phase 1 study delafloxacin doses
up to three-fold higher than the currently
labeled dose (900 mg) did not induce clinically
meaningful changes in the QTc, while moxifloxacin, which served as the positive control,
produced predicted prolongation of the QTc
interval [56, 61]. In phase 3 studies, no occurrences of drug-induced arrhythmias were
reported [56].
Administration of fluoroquinolones has
emerged as one of the most important risk factors for C. difficile-associated diarrhea (CDAD)
caused by the hypervirulent RT027 strain [62].
In early surveillance studies, delafloxacin
demonstrated potent activity against many
anaerobic species [28]. In particular, it showed
greater in vitro activity against C. difficile than
comparator fluoroquinolones; however, activity
against the RT027 strain was considerably lower
[30]. The impact of delafloxacin, of which
35–50% is eliminated unchanged in the feces,
on bowel flora is unknown at this time. Two
cases of CDAD were reported among patients
enrolled in the delafloxacin arms of phase 2 and
3 studies [56]. Both patients were noted to have

Infect Dis Ther (2018) 7:197–217

a number of risk factors for CDAD besides
antibiotic exposure [56].
Fluoroquinolones are not known to commonly cause harmful effects on the kidneys;
however, the vehicle used to deliver IV delafloxacin, SBECD, may be problematic in
patients with renal impairment [63]. A reduced
delafloxacin dose (200 mg IV q12 h) is therefore
recommended in patients with an eGFR \
30 ml/min/1.73 m2 and a switch to oral delafloxacin as soon as clinically indicated [6].
To summarize, the available data have not
demonstrated significant safety concerns for
delafloxacin. However, as with all new antibiotics, assessment of safety is limited by the
small number of healthy subjects and patients
to whom it has been administered. Exclusion
criteria in completed phase 3 trials also limit the
generalizability of safety findings to patients
who may be more likely to receive this agent in
the clinic, i.e., those with pre-existing organ
dysfunction and a higher degree of baseline
comorbidities. Nevertheless, the additional
quasi-experimental data, which included positive controls for two important class AEs, phototoxicity and QTc prolongation, are reassuring.

DRUG INTERACTIONS
Like other fluoroquinolones, delafloxacin forms
insoluble chelation complexes with multivalent
cations in the GI tract resulting in a substantial
decrease in oral absorption of the antibiotic,
and concomitant administration should be
avoided [6]. At clinically relevant concentrations, delafloxacin does not inhibit cytochrome
P450 isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1 or 3A4/5 [56]. Delafloxacin
demonstrated mild induction of CYP3A4 at
clinically relevant concentrations in vitro;
however, it did not affect the Cmax and AUC
values for midazolam (a sensitive CYP3A4 substrate) or its metabolite when administered to
healthy volunteers prior to midazolam administration [56]. Delafloxacin is a substrate of
breast cancer-related protein (BCRP) and a
potential substrate of P-glycoprotein [56].
However, only modest increases in delafloxacin
concentrations are anticipated when co-
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administered with BCRP or P-glycoprotein
inhibitors, and the clinical significance is
expected to be minimal [56]. The impact of
P-glycoprotein inducers, such as rifampicin, on
delafloxacin exposure has not been reported.

PLACE IN THERAPY
AND CONCLUSIONS
ABSSSI is a popular market-entry indication for
pharmaceutical companies developing new
antimicrobials targeting MRSA [64–67]. Delafloxacin recently received FDA approval in this
setting based on registry studies showing it to be
an effective and well-tolerated alternative [5].
Notable advantages of delafloxacin for the
treatment of ABSSSI include the availability of
both parenteral and oral formulations, a low
potential for drug–drug interactions and reassuring clinical and experimental data pertaining
to key class-adverse effects such as cardiotoxicity and phototoxicity. With the availability of a
variety of new agents for the treatment of
ABSSSI, it will be important to determine which
agents are most suitable for specific patients on
the basis of coverage (broad versus narrow
spectrum), delivery (IV or PO) and potential for
adverse reactions and compliance (single versus
multiple daily dosing).
Of particular concern, fluoroquinolone use
has been associated with increased rates of colonization and infection with MRSA, ESBL-producing Enterobacteriaceae and [5, 68–70] the
hypervirulent C. difficile RT027 strain [62, 70].
Recent international guidelines for the treatment of a number of infectious diseases explicitly
recognize
the
ecologic
AEs
of
fluoroquinolones as important factors in therapeutic decision-making and have called for
more restricted use of these agents [71, 72]. As
antibiotic innovation continues to move forward, greater attention needs to be placed on
pinpointing unique properties of novel agents
to assist in determining their specific therapeutic niche with respect to areas of unmet medical
need while limiting collateral damage.
There are many important areas of unmet
need in the treatment of gram-positive infections for which experimental data suggest the
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distinctive structural and chemical properties of
delafloxacin may be harnessed to make it a
particularly valuable addition to the antibiotic
armamentarium. Improving long-term outcomes in patients with biofilm-associated
infections is a critical unmet need, and delafloxacin’s potent activity against S. aureus
embedded in biofilm suggests a potential role in
this setting [41, 42]. Antibiotics that are capable
of eradicating intracellular non-replicating persister bacteria in bone, prosthetic device-associated infections and deep-seated abscesses are
clearly an unmet medical need, and delafloxacin’s excellent intracellular penetration,
especially in the acidic conditions that are
characteristic of these difficult to treat infections, points to another therapeutic niche [7]. A
potent oral agent would be particularly desirable in these settings because prolonged therapy
with IV antibiotics is often necessary but associated with tremendous expense, inconvenience and harmful effects associated with
extended catheterization. The prospect of
combination therapy with delafloxacin and
rifampicin for these infections is intriguing, and
future research investigating the potential synergistic activity in biofilm models would be
valuable. Delafloxacin’s bactericidal activity
and excellent pulmonary penetration [36] are
also suggestive of a promising role against
pneumonia. The diminishing pool of effective
antibiotics for gonorrhea represents an urgent
public health threat [73]. Although a single oral
dose of delafloxacin was not sufficiently effective for uncomplicated gonorrhea infection, its
potent in vitro activity against this pathogen
[24] suggests that evaluations of alternative
dosing schedules would be worthwhile.
Struggles with resistance will not cease with
the availability of new antibiotics, and we must
learn how to optimally use and not abuse
promising new agents such as delafloxacin. An
oral antibiotic with in vitro activity against
MRSA, Pseudomonas spp., anaerobes, and atypical organisms will attract many prescribers, and
antimicrobial stewards will be tasked with
implementing it appropriately into practice. As
clinicians contemplate how to best incorporate
delafloxacin into infectious disease treatment
strategies, additional data pertaining to whether
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the promising experimental data detailed in
this review do indeed translate into improved
outcomes for patient with difficult to treat
infections are greatly anticipated.
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